• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Reported Saturday, Protagonist Therapeutics And Takeda Highlight VERIFY And THRIVE Data Showing Long-Term Hematocrit Control And Reduced Therapeutic Phlebotomy In PV At ASH 2025

    Benzinga·12/08/2025 09:05:23
    Listen to the news
    • 52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety Signals
    • These Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary Endpoints
    • Patients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52
    • Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline